Hematopoietic stem cell transplantation for T315I-mutated chronic myelogenous leukemia

Annals of Transplantation

Volumn 15, Issue 2, 2010, Pages 68-70

  Basak, Grzegorz Wladyslaw ^a   Torosian, Tigran ^a   Snarski, Emilian ^a   Niesiobedzka, Joanna ^a   Majewski, Miroslaw ^b   Gronkowska, Anna ^a   Urbanowska, Elzbieta ^a   Wiktor Jedrzejczak, Wieslaw ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

Author keywords

Bone marrow transplantation; CML; Imatinib; T315I mutation

Indexed keywords

ALPHA INTERFERON; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; GANCICLOVIR; GLUCOCORTICOID; IMATINIB; METHOTREXATE; PROTEIN TYROSINE KINASE INHIBITOR; THYMOCYTE ANTIBODY; BCR ABL PROTEIN; PROTEIN KINASE INHIBITOR;

ACUTE GRAFT VERSUS HOST DISEASE; ADRENAL INSUFFICIENCY; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CASE REPORT; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; DRUG DOSE ESCALATION; GENE MUTATION; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA REMISSION; LOW DRUG DOSE; MALE; MESENTERIC VEIN THROMBOSIS; PHILADELPHIA CHROMOSOME POSITIVE CELL; PHOTOTHERAPY; STAPHYLOCOCCAL BACTEREMIA; ALLOTRANSPLANTATION; AMINO ACID SUBSTITUTION; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACCELERATED PHASE; MISSENSE MUTATION; ONCOGENE; REMISSION;

ADULT; AMINO ACID SUBSTITUTION; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENES, ABL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACCELERATED PHASE; MALE; MUTATION, MISSENSE; PROTEIN KINASE INHIBITORS; REMISSION INDUCTION; TRANSPLANTATION, HOMOLOGOUS;

EID: 77954656108     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Baccarani M, Saglio G, Goldman J, et al: Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 2006; 108: 1809-20
2. Hehlmann R, Hochhaus A, Baccarani M: Chronic myeloid leukaemia. Lancet, 2007; 370: 342-50
3. Gorre ME, Mohammed M, Ellwood K et al: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 2001; 293: 876-80
4. Apperley JF: Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol, 2007; 8: 1018-29